SYNCOM FORMULATIONS (INDIA) LTD.-$

Syncom Formulations India Ltd has announced Wednesday, September 23, 2026, as the record date to determine shareholder entitlement for a proposed 10% dividend (Rs. 0.10 per equity share) for the financial year 2025-26. This dividend is subject to approval at the company's 38th Annual General Meeting (AGM) scheduled for September 30, 2026. Shareholders have the option to voluntarily waive their dividend entitlement by submitting a form by September 26, 2026. The AGM will be conducted via Video Conferencing.

Syncom Formulations India Ltd has dispatched letters to shareholders whose email addresses are not registered, informing them about the availability of the Annual Report for FY 2025-26. The report and the notice for the 38th Annual General Meeting (AGM), scheduled for September 30, 2026, are accessible via web links and the company's website. Shareholders can request physical copies by emailing finance@sfil.in. The company also noted that these documents are available on the BSE, NSE, and CDSL websites.

Syncom Formulations India Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed pursuant to SEBI (LODR) Regulations, 2015, details the company's operations, employee data, and sustainability initiatives. The company is also preparing to file the BRSR in XBRL format and will make it available on its website. The report indicates that the company's primary business activity is the manufacture and sale of pharmaceuticals, accounting for 92.62% of its turnover. Exports constitute a significant portion of its revenue, with 82.94% of turnover coming from international sales.

Syncom Formulations India Ltd has announced its 38th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 2:00 PM IST. The meeting will be conducted through Video Conferencing (VC)/Other Audio Visual Means (OAVM), with the registered office in Mumbai deemed as the venue. Key agenda items include the adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026, declaration of a 10% dividend on equity shares, re-appointment of a director retiring by rotation, ratification of cost auditor remuneration, and confirmation of an additional director's appointment.

Syncom Formulations India Ltd has submitted its 38th Annual Report for the financial year 2025-26, as per SEBI (LODR) Regulations, 2015. The report includes the Balance Sheet, Profit and Loss statement, Cash Flow statement, Statement of Changes in Equity, Board's Report, Corporate Governance Report, BRSR, and Auditors' Report. The company has scheduled its 38th Annual General Meeting (AGM) for Wednesday, September 30, 2026, to be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The annual report and related documents are available on the company's website. The filing also details changes in the Board of Directors and Key Managerial Personnel, with several appointments and resignations effective around August 2026.

Syncom Formulations (India) Limited announced strong financial results for the first quarter ended June 30, 2026. Consolidated total income grew by 8% to ₹133.36 crore from ₹122.94 crore in the corresponding quarter last year. Profit before tax surged by 59% to ₹332.25 crore, and profit after tax increased by approximately 58% to ₹24.85 crore, up from ₹15.75 crore year-on-year. Earnings per share improved to ₹0.26 from ₹0.17. Revenue from operations saw a nearly 7% increase, reaching ₹125.53 crore. The company's performance is attributed to its ethical, prescription-led model, quality manufacturing, and disciplined cost control. The Board has recommended a final dividend of ₹0.10 per equity share for FY26, subject to shareholder approval.

Syncom Formulations India Ltd has announced the details for remote e-voting for its 38th Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 30, 2026, at 2:00 p.m. Members can cast their votes electronically through remote e-voting and e-voting at the AGM. The cut-off date for e-voting entitlement is September 23, 2026. Voting will commence on September 27, 2026, at 9:00 A.M. and conclude on September 29, 2026, at 5:00 P.M. CDSL is the agency providing the e-voting platform and conducting the AGM via VC/OAVM. CS Anish Gupta will serve as the scrutinizer.

Syncom Formulations India Ltd announced significant changes in its board and senior management. Shri Kedarmal Shankarlal Bankda resigned as Whole-time Director, Shri Vijay Shankarlal Bankda resigned as Managing Director, and Shri Rahul Vijay Bankda resigned as Chief Financial Officer (CFO). Concurrently, Smt. Rinki Ankit Bankda has been appointed as Additional Director and Whole Time Director, and Shri Rahul Vijay Bankda has been appointed as Additional Director and Managing Director. Shri Ankur Vijay Bankda has been redesignated as CFO. These changes are effective from August 11/12, 2026, and are subject to shareholder approval.

Syncom Formulations India Ltd announced the appointment of M/s M. Goyal & Co. as Cost Auditor and M/s Bansal & Agrawal as Internal Auditor for the financial year 2026-27. The decisions were made by the Board of Directors on August 11, 2026, based on the recommendations of the Audit Committee. The company also provided detailed disclosures as required by SEBI (LODR) Regulations, 2015.

Syncom Formulations India Ltd has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Audit Committee and the Board of Directors on August 11, 2026. The company operates in three segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The financial results will be published in English and Marathi newspapers and filed in XBRL format on the company's website.